naa a22 4500 510764037 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130401xx s 000 0 eng 10.1007/s12094-012-0936-6 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0936-6 Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients [Elektronische Daten] [Xu Liang, Jie Zhang, Yulin Zhu, Yuanli Lu, Xinna Zhou, Zheng Wang, Jing Yu, Ying Yan, Lijun Di, Li Che, Hanfang Jiang, Bin Shao, Xiaoli Wang, Huabing Yang, Herbert Lyerly, Jun Ren] Aim: This study was designed to explore the genetic polymorphism of IL-10 (−1082A/G, −592A/C, −819T/C), TNF-α (−308G/A) with susceptibility to docetaxel-induced liver injury (DILI) in Chinese breast cancer patients. Methods: The targeted genetic polymorphisms of IL10-1082G/A, IL10-592A/C, IL10-819T/C, TNF-308G/A from 40 patients with DILI were assayed by matrix-assisted laser desorption/ionization-time of flight of Sequenom. Results: AA genotype of IL10-592 and TT of IL10-819 significantly increased incidence of DILI (P=0.005, OR=3.137). No differences of TNF gene polymorphism between the two groups were seen. Conclusion: The genetic polymorphism of the IL10-592A/C AA genotype and IL10-819T/C TT genotype was predominantly conferred to the incidence of docetaxel-induced liver injury. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Breast cancer nationallicence Drug-induced liver injury nationallicence Tumor necrosis factor nationallicence Interleukin 10 nationallicence Gene polymorphism nationallicence Liang Xu Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Zhang Jie Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Zhu Yulin Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Lu Yuanli Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Zhou Xinna Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut Wang Zheng Beijing Chaoyang Hospital, CMU, Beijing, China aut Yu Jing Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Yan Ying Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Di Lijun Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Che Li Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Jiang Hanfang Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Shao Bin Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut Wang Xiaoli Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut Yang Huabing Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut Lyerly Herbert Duke University Medical Center, 203 Research Drive, Rm 433, Box 2606, 27710, Durham, NC, USA aut Ren Jun Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 331-334 1699-048X 15:4<331 2013 15 12094 https://doi.org/10.1007/s12094-012-0936-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0936-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liang Xu Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Zhang Jie Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Zhu Yulin Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Lu Yuanli Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Zhou Xinna Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut NATIONALLICENCE 700 1- Wang Zheng Beijing Chaoyang Hospital, CMU, Beijing, China aut NATIONALLICENCE 700 1- Yu Jing Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Yan Ying Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Di Lijun Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Che Li Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Jiang Hanfang Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Shao Bin Department of Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China aut NATIONALLICENCE 700 1- Wang Xiaoli Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut NATIONALLICENCE 700 1- Yang Huabing Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut NATIONALLICENCE 700 1- Lyerly Herbert Duke University Medical Center, 203 Research Drive, Rm 433, Box 2606, 27710, Durham, NC, USA aut NATIONALLICENCE 700 1- Ren Jun Capital Medical University Cancer Center, Beijing Shijitan Hospital, CMU, 10 Tieyi Road, 100038, Beijing, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 331-334 1699-048X 15:4<331 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer